Ticiana Leal, MD, and Sandip P. Patel, MD, discuss the treatment landscape for patients with advanced non–small cell lung cancer and the emerging role of targeting HER3.
October 12th 2023
Medical oncologists specializing in lung cancer give an overview of the current treatment landscape for patients with EGFR-mutated non–small cell lung cancer (NSCLC).
Sandip P. Patel, MD, discusses treatment options available for patients with EGFR-mutated NSCLC who progress on EGFR TKIs and platinum-based chemotherapy.
October 19th 2023
Ticiana Leal, MD, gives a comprehensive overview of treatment options for patients with EGFR-mutated NSCLC who progress on osimertinib therapy.
Expert perspectives on unmet needs and therapies available for patients with EGFR-mutated non–small cell lung cancer.
October 26th 2023
A medical oncologist discusses the role of HER3 in the treatment of non–small cell lung cancer and provides an overview of the HERTHENA-Lung01 clinical trial.
Experts on lung cancer review key data from the HERTHENA-Lung01 study investigating patritumab deruxtecan (HER3-DXd) in patients with advanced EGFR-mutated NSCLC.
November 2nd 2023
Medical oncologists discuss the toxicity profile of patritumab deruxtecan and the safety outcomes from HERTHENA-Lung01 in non–small cell lung cancer.
Clinical insights on where patritumab deruxtecan might fit in the treatment paradigm for patients with advanced non–small cell lung cancer.
November 9th 2023
Ticiana Leal, MD, and Sandip P. Patel, MD, discuss clinical trials evaluating the use of patritumab deruxtecan in patients with non–small cell lung cancer and remaining unmet needs.